Search for drugs:
Typing the drug name to query
FELBAMATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Postmarketing Adverse Event Reports
- Voluntary reports of adverse events in patients taking felbamate (usually in conjunction with other drugs) have been received since market introduction and may have no causal relationship with the drug(s). These include the following by body system:
- Cardiovascular: atrial fibrillation, atrial arrhythmia, cardiac arrest, torsade de pointes, cardiac failure, hypotension, hypertension, flushing, thrombophlebitis, ischemic necrosis, gangrene, peripheral ischemia, bradycardia, Henoch-Schönlein purpura (vasculitis).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
917
38380670
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- N03AX10 - felbamate
- N03AX - Other antiepileptics
- N03A - ANTIEPILEPTICS
- N03 - ANTIEPILEPTICS
- N - NERVOUS SYSTEM
Active Ingredient:FELBAMATE
Active Ingredient UNII:X72RBB02N8
Drugbank ID:DB00949
PubChem Compound:3331
CTD ID:D000078328
PharmGKB:PA449590
CAS Number:25451-15-4
Dosage Form(s):suspension
Route(s) Of Administrator:oral
Daily Dose:
- 2400.0 mg/day N03AX10
Chemical Structure: 
SMILE Code:
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.